DexCom's Surge Masks Deeper Industry Issues DexCom Inc. 's recent stock jump has provided a welcome respite for investors, but it distracts from more pressing concerns within the medical technology sector.
The company's decision to raise its revenue growth target and non GAAP operating profit margin may be music to Wall Street's ears, but what does this say about the industry as a whole?
The appointment of two new independent directors with experience in medical technology and operations is a nod towards corporate governance best practices, particularly given DexCom's collaboration with activist investor Elliott Investment Management LP.